The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma - Episode 11
In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.